Of interest, the presence of HαT has been investigated as a potential additive trigger for clinical manifestations in SM patients, as severe episodes were twice more frequent in individuals with both SM and HαT than in those with SM but without HαT (17, 18). This evidence concerns the gene TMPRSS11D and systemic mastocytosis.